Germany Blood Glucose Monitoring Market Size

Germany Blood Glucose Monitoring Market Analysis

The Germany Blood Glucose Monitoring Market size is estimated at USD 1.69 billion in 2024, and is expected to reach USD 2.43 billion by 2029, growing at a CAGR of 7.47% during the forecast period (2024-2029).

One of the most significant risk factors for severe COVID-19 was diabetes mellitus. This risk was believed to be influenced by several variables frequently present in diabetes mellitus, such as advanced age, hyperglycemia, and underlying conditions (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic, so managing or delaying diabetes became more important than ever before. Following a COVID-19 infection, various studies suggested that reduced numbers of insulin secretory granules in beta cells and impaired glucose-stimulated insulin secretion were observed in the affected patients. In addition, post the pandemic, some patients developed insulin resistance and had elevated blood glucose levels, although they had no previous history of diabetes.

Blood glucose monitoring observes patterns in the fluctuation of blood glucose levels in response to diet, exercise, medications, and pathological processes associated with blood glucose fluctuations such as diabetes. Unusually high or low blood glucose levels can potentially lead to acute and or chronic, life-threatening conditions. Managing diabetes to improve patient outcomes requires a complex multidisciplinary approach. Appropriate and timely blood glucose monitoring allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have an increased risk of being hospitalized and, thus, incur more healthcare expenses than non-diabetic people. People with diabetes face a higher chance of experiencing serious complications. Germany is one of the developed countries and advanced healthcare facilities. Technologies like continuous glucose monitoring are getting more rapidly adopted in Germany than in other developing countries. Moreover, reimbursement and pricing policies are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies.